血流动力学稳定的少尿危重症患者:非干预随访与500 mL液体负荷的随机对照先导试验
该随机对照先导试验纳入130例血流动力学稳定、少尿至少2小时(尿量<0.5 mL/kg/h)的危重症患者,1:1随机分为非干预随访2小时组(FU)与30分钟内输注500 mL晶体液组(FB)。主要终点为随机化后2小时尿量较随机化前2小时尿量倍增的患者比例:FU组10/63(15.9%)vs FB组22/67(32.8%),RR 0.49(95%CI 0.23-0.71),P=0.026。FB组尿量中位变化为19 mL,FU组为-7 mL,中位差-23 mL(95%CI -36至-10),P=0.001;FB组少尿持续时间更短(中位差2小时,P=0.038),但研究日累积液体平衡更高(中位差-387 mL,P<0.001)。作者认为,对少尿患者采取随访观察策略虽然尿量改善频率较低,但累积液体平衡更低。
要点
- 主要终点:随机化后2小时尿量倍增比例FU组15.9%(10/63)vs FB组32.8%(22/67),RR 0.49(95%CI 0.23-0.71),P=0.026
- 尿量中位变化:FU组-7 mL vs FB组19 mL,中位差-23 mL(95%CI -36至-10),P=0.001
- 少尿持续时间中位数:FU组4小时 vs FB组2小时,中位差2小时(95%CI 0-4),P=0.038
- 研究日累积液体平衡中位数:FU组678 mL vs FB组1071 mL,中位差-387 mL(95%CI -635至-213),P<0.001
- 作者结论:对少尿采取随访观察策略较500 mL晶体液负荷改善尿量的频率更低,但累积液体平衡更低
适用人群与场景
- 血流动力学稳定的危重症患者,少尿至少2小时(尿量<0.5 mL/kg/h)
- 分层变量为是否合并脓毒症或急性肾损伤(AKI)
诊断标准与关键阈值
- 少尿定义:尿量<0.5 mL/kg/h,持续至少2小时
- 主要终点:随机化后2小时尿量除以随机化前2小时尿量≥2(尿量倍增)
处置流程与药物剂量
- 非干预随访组:随机化后随访观察2小时,不予液体负荷
- 液体负荷组:30分钟内输注500 mL晶体液
研究设计与关键结果
- 研究类型:随机对照先导试验,纳入130例,1:1随机分为非干预随访(FU)组与500 mL晶体液负荷(FB)组
- 主要终点:随机化后2小时尿量倍增比例FU组15.9%(10/63)vs FB组32.8%(22/67),RR 0.49(95%CI 0.23-0.71),P=0.026
- 尿量中位[IQR]变化:FU组-7[-19至17] mL vs FB组19[0-53] mL,中位差-23 mL(95%CI -36至-10),P=0.001
- 少尿持续时间中位[IQR]:FU组4[2-8]小时 vs FB组2[0-6]小时,中位差2小时(95%CI 0至4),P=0.038
- 研究日累积液体平衡中位[IQR]:FU组678[518-1029] mL vs FB组1071[822-1505] mL,中位差-387 mL(95%CI -635至-213),P<0.001
- 结局采用双侧回归校正分层变量(是否合并脓毒症或AKI),OR转换为RR(95%CI)
证据类型、等级与局限
- 证据类型:随机对照先导试验
- 局限:原文未报告局限性
对床旁实践的改变
- 对血流动力学稳定、少尿至少2小时(尿量<0.5 mL/kg/h)的危重症患者,非干预随访2小时较500 mL晶体液负荷尿量倍增比例更低(15.9% vs 32.8%),但累积液体平衡更低(中位678 mL vs 1071 mL)
- 作者结论:随访观察策略改善尿量的频率较低,但累积液体平衡更低
指南或共识出处
- 试验注册:ClinicalTrials.gov,NCT02860572,注册日期2016年8月9日
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Fluid bolus therapy is a common intervention to improve urine output. Data concerning the effect of a fluid bolus on oliguria originate mainly from observational studies and remain controversial regarding the actual benefit of such therapy. We compared the effect of a follow-up approach without fluid bolus to a 500 mL fluid bolus on urine output in hemodynamically stable critically ill patients with oliguria at least for 2 h (urine output < 0.5 mL/kg/h) in randomized setting.
METHODS: We randomized 130 patients in 1:1 fashion to receive either (1) non-interventional follow-up (FU) for 2 h or (2) 500 mL crystalloid fluid bolus (FB) administered over 30 min. The primary outcome was the proportion of patients who doubled their urine output, defined as 2-h urine output post-randomization divided by urine output 2 h pre-randomization. The outcomes were adjusted for the stratification variables (presence of sepsis or AKI) using two-tailed regression. Obtained odds ratios were converted to risk ratios (RR) with 95% confidence intervals (CI). The between-group difference in the continuous variables was compared using mean or median regression and expressed with 95% CIs.
RESULTS: Altogether 10 (15.9%) of 63 patients in the FU group and 22 (32.8%) of 67 patients in FB group doubled their urine output during the 2-h period, RR (95% CI) 0.49 (0.23-0.71), P = 0.026. Median [IQR] change in individual urine output 2 h post-randomization compared to 2 h pre-randomization was - 7 [- 19 to 17] mL in the FU group and 19[0-53] mL in the FB group, median difference (95% CI) - 23 (- 36 to - 10) mL, P = 0.001. Median [IQR] duration of oliguria in the FU group was 4 [2-8] h and in the FB group 2 [0-6] h, median difference (95%CI) 2 (0-4) h, P = 0.038. Median [IQR] cumulative fluid balance on study day was lower in the FU group compared to FB group, 678 [518-1029] mL versus 1071 [822-1505] mL, respectively, median difference (95%CI) - 387 (- 635 to - 213) mL, P < 0.001.
CONCLUSIONS: Follow-up approach to oliguria compared to administering a fluid bolus of 500 mL crystalloid in oliguric patients improved urine output less frequently but lead to lower cumulative fluid balance. Trial registration clinical.
TRIALS: gov, NCT02860572. Registered 9 August 2016.
参考来源
- Inkinen N, Pettilä V, Valkonen M, et al. Non-interventional follow-up versus fluid bolus in RESPONSE to oliguria in hemodynamically stable critically ill patients: a randomized controlled pilot trial. Crit Care. 2022. PMID: 36550559. doi:10.1186/s13054-022-04283-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。